Please assess the completion status of the following clinical trial:

Trial Title: Treating H. Pylori in Parkinson's Patients With Motor Fluctuations

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Adults diagnosed with idiopathic Parkinson's disease, Hoehn \& Yahr stage 2-4 in the off state, with no other concomitant neurologic diseases.~* Stable (≥30 days) Parkinson's disease therapy, with demonstrable medication efficacy, but with wearing off phenomenon present between levodopa doses (average off time ≥3 hours off time/day).~* Levodopa therapy required; Any formulation (e.g. Sinemet, Sinemet CR, Stalevo) is acceptable. Parkinson's disease treatment may also include any of the following medications or classes: non-ergot dopamine agonists, COMT inhibitors, MAO-B inhibitors, amantadine, anticholinergics.~* Positive for H. pylori IgG Ab by serum ELISA (before inclusion in randomized treatment arms).~Exclusion criteria:~* Current abdominal pain, unexplained nausea/vomiting, or gastrointestinal bleeding.~* History of gastric cancer, peptic ulcer, duodenal ulcer, or other gastric or duodenal lesions.~* History of previous gastric surgery.~* History of previous brain surgery for Parkinson's disease.~* Family history of gastric cancer.~* Prior treatment for H. pylori+ status.~* Recent use (previous 4 weeks) of proton-pump inhibitor, amoxicillin, or clarithromycin.~* Allergy or sensitivity to penicillin, amoxicillin, clarithromycin, or omeprazole.~* Use of drugs affecting gastric motility (e.g. domperidone, metoclopramide).~* Inability to tolerate or participate in testing in the morning in an off state.~* Inability to communicate effectively with study personnel in English.~* Pregnancy.

- Gender: MALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Active-placebo (Type: OTHER): These subject receive treatment with active triple therapy followed by treatment with placebo therapy.
- Placebo-active (Type: OTHER): These subject receive treatment with placebo therapy followed by treatment with active triple therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).